Cholangiocarcinoma News

Hot Topics on Cholangiocarcinoma at the 2023 Cholangiocarcinoma Foundation Annual Conference

Videos — April 11, 2023

Featuring:

Melinda Bachini
Director of Advocacy
Cholangiocarcinoma Foundation
Billings, MT
Juan W. Valle, MB ChB, MSc, FRCP
Professor and Honorary Consultant
Medical Oncology
Manchester Academic Health Sciences
Centre Institute of Cancer Studies
University of Manchester
Lead, The Christie European
Neuroendocrine Tumour Society
Centre of Excellence
Manchester, UK

On April 14, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 Cholangiocarcinoma Foundation Annual Conference. In addition, we provided our perspectives on the impact of the data on the management of patients with CCA.

Related Items

CCA Summit Live from ESMO 2022
By Juan W. Valle, MB ChB, MSc, FRCP
Videos
On September 21, 2022, I presented an overview of key abstracts on biliary tract cancer (BTC) presented at the 2022 annual meeting of the European Society for Medical Oncology. In addition, I provided my perspective on the impact of the data on the management of patients with BTC.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Durvalumab in Combination with Gemcitabine/Cisplatin in Advanced BTC (TOPAZ-1)
June/July 2022, Vol 3, No 2
A phase 3 study showed that the addition of cytotoxic chemotherapy to the PD-L1 inhibitor durvalumab was associated with promising antitumor activity as first-line treatment for patients with advanced biliary tract cancer.
Novel Approaches to Overcome FGFR Resistance
June/July 2022, Vol 3, No 2
In a Cholangiocarcinoma (CCA) Foundation meeting session, Dr Francesco Facchinetti from the Gustave Roussy Cancer Campus discussed novel approaches to overcome FGFR resistance in FGFR-altered CCA.
The Role of ctDNA in Promoting a Cure for CCA
June/July 2022, Vol 3, No 2
In a Cholangiocarcinoma (CCA) Foundation meeting session, Dr Zachariah H. Foda from the Johns Hopkins School of Medicine discussed the role of circulating tumor DNA in early detection and disease monitoring for CCA.
Deep Immune Profiling of Intrahepatic Cholangiocarcinoma
June/July 2022, Vol 3, No 2
At the Cholangiocarcinoma (CCA) Foundation meeting, Dr Mark Yarchoan from the Johns Hopkins School of Medicine presented his fellowship project focused on deciphering immune micro-environments in molecularly defined CCA subsets.
Case-Based Panel Discussion: Multidisciplinary Care of CCA
June/July 2022, Vol 3, No 2
At the 2022 annual meeting of the Cholangiocarcinoma (CCA) Foundation, a case-based panel discussion focused on multidisciplinary care of CCA.
Targeted Therapies on the Horizon for CCA
June/July 2022, Vol 3, No 2
Rachna T. Shroff, MD, MS, Chief, Section of Gastrointestinal Medical Oncology, University of Arizona Cancer Center, Tucson, reviewed promising clinical data regarding novel targeted therapies currently under clinical investigation for the treatment of cholangiocarcinoma.
Why We Need Correct ICD Coding for CCA
June/July 2022, Vol 3, No 2
At the 2022 Cholangiocarcinoma (CCA) Foundation annual meeting, Dr Shahid Khan, Clinical Senior Lecturer at Imperial College London, discussed the need for correct International Classification of Diseases coding for CCA.
Influence of the Microbiome in Cancer
June/July 2022, Vol 3, No 2
One session at the 2022 Cholangiocarcinoma Foundation annual meeting focused on the role of microbiome in the pathogenesis of hepatobiliary cancers.
Caring for a Loved One with CCA: A Son’s Perspective
June/July 2022, Vol 3, No 2
At the 2022 Cholangiocarcinoma (CCA) Foundation annual meeting, Ambuj Srivastava shared his experience as a current caregiver for his dad who was diagnosed with stage 2 extrahepatic CCA.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: